MRI-TRUS Fusion Prostate Biopsy Results
Author Information
Author(s): Tomaz Smrkolj, Milena Taskovska, Iztok Ditz, Klemen Cernelc, Simon Hawlina
Primary Institution: Department of Urology, Ljubljana University Medical Centre, Ljubljana, Slovenia
Hypothesis
The study aims to evaluate the performance and learning curve of the MRI-TRUS fusion biopsy process in a high-volume clinical setting.
Conclusion
MRI-TRUS fusion targeted biopsy significantly improves the overall rate of prostate cancer detection compared to systematic biopsy alone.
Supporting Evidence
- The proportion of patients with positive histopathologic results for targeted biopsy was 53.9%.
- Clinically significant prostate cancer was confirmed in 34.7% of the biopsy lesions.
- The learning curve for MRI-TRUS fusion biopsy showed no significant differences in outcomes over time.
- Positive biopsy lesions were further analyzed by PIRADS and Gleason scores.
Takeaway
Doctors used a special imaging technique to find prostate cancer better, and it worked really well without needing a lot of practice.
Methodology
The study involved 293 patients who underwent MRI-TRUS fusion targeted biopsy, analyzing the proportion of positive histopathologic results and assessing the learning curve.
Potential Biases
The variability in reporting and performing MRI-TRUS fusion biopsy among different practitioners could affect the study's conclusions.
Limitations
The study had a relatively large number of participating urologists and radiologists from different centers, which may have introduced variability in results.
Participant Demographics
Patients included were those with at least one clearly defined PIRADS ≥ 3 lesion, aged between 35 and 91 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website